Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT conditioning regimens for severe treatment-resistant relapsing multiple sclerosis
ACTRN12622000536763Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, antithymocyte globulin rabbit, carmustine, etoposide, cytarabine and 1 more in multiple sclerosis (MS) (4 arms), sponsored by St Vincent's Hospital. Primary endpoints: Length of hospital stay after AHSCT, Time to neutrophil engraftment and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulin rabbitcarmustineetoposidecytarabine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12622000536763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000536763.